ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS)

MLA

Victoria Soldatenkova, et al. “ANNOUNCE: A Randomized, Placebo (PBO)-Controlled, Double-Blind, Phase (Ph) III Trial of Doxorubicin (Dox) + Olaratumab versus Dox + PBO in Patients (Pts) with Advanced Soft Tissue Sarcomas (STS).” Journal of Clinical Oncology, vol. 37, June 2019, p. LBA3. EBSCOhost, https://doi.org/10.1200/jco.2019.37.18_suppl.lba3.

APA

Victoria Soldatenkova, Yoichi Naito, Albiruni Ryan Abdul Razak, Andrew J. Wagner, Axel Le Cesne, Ashwin Shahir, Se Hoon Park, William D. Tap, Jennifer Wright, Akira Kawai, Chueh-Chuan Yen, Brian A. Van Tine, Robin L. Jones, Gary Mo, Javier Martin Broto, Kristen N. Ganjoo, Patrick Schöffski, Zsuzsanna Papai, Anders Krarup-Hansen, & Alexander I. Spira. (2019). ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS). Journal of Clinical Oncology, 37, LBA3. https://doi.org/10.1200/jco.2019.37.18_suppl.lba3

Chicago

Victoria Soldatenkova, Yoichi Naito, Albiruni Ryan Abdul Razak, Andrew J. Wagner, Axel Le Cesne, Ashwin Shahir, Se Hoon Park, et al. 2019. “ANNOUNCE: A Randomized, Placebo (PBO)-Controlled, Double-Blind, Phase (Ph) III Trial of Doxorubicin (Dox) + Olaratumab versus Dox + PBO in Patients (Pts) with Advanced Soft Tissue Sarcomas (STS).” Journal of Clinical Oncology 37 (June): LBA3. doi:10.1200/jco.2019.37.18_suppl.lba3.